See the DrugPatentWatch profile for sitagliptin
What patents cover sitagliptin (Januvia) and who holds them?
Sitagliptin (the active ingredient in Januvia) is protected by a set of patents that typically include compound claims and related coverage such as formulations, manufacturing, and new uses. Public detail on which specific sitagliptin patents are currently in force depends on the country and the patent register consulted (for example, US vs. EU vs. UK), and on whether coverage is extended by regulatory exclusivity or patent term adjustments.
When do sitagliptin patents expire?
The expiration timeline depends on jurisdiction and the specific patent(s) covering sitagliptin in that market. In practice, generics may still face barriers even after the “last compound patent” date because follow-on patents (for example, on formulations or dosing) and regulatory exclusivities can extend market protection in certain regions.
Can generic sitagliptin enter before all patents expire?
In many jurisdictions, generics can file for approval using abbreviated pathways, but commercial launch is often delayed until patents and exclusivities permitting infringement-free marketing have expired (or have been successfully challenged). Whether “early launch” is possible depends on patent validity and scope, and on local procedures for patent disputes.
Are there biosimilar-style rules for sitagliptin?
Sitagliptin is a small-molecule drug, not a biologic. So the pathways and patent-expiry dynamics are governed by standard small-molecule generic competition rules, not biosimilar frameworks.
What should I check to find the exact patent expiry for sitagliptin in my country?
To get the precise patent expiration for sitagliptin where you live, you typically need:
- The brand(s) and marketing authorization holder in that country (e.g., Januvia and its local MAH).
- The patent list for the active ingredient and product, from the national patent database.
- Any supplemental protections (for example, regulatory exclusivity, if applicable), and whether patents have lapsed or been invalidated.
If you tell me the country, I can narrow it down
Patent status is jurisdiction-specific. If you share which country (and, if you want, whether you mean the US, EU, UK, or another market), I can focus on the relevant sitagliptin patent families and the expected expiry timing for that specific region.
Sources
No sources were provided in your prompt, and I don’t have access to external patent databases from here.